Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

edwards lifesciences corp. - EW

EW

Close Chg Chg %
80.92 -0.67 -0.82%

Pre-Market

80.25

-0.67 (0.82%)

Volume: 3.18M

Last Updated:

Sep 8, 2025, 4:00 PM EDT

Trade Now

Company Overview: edwards lifesciences corp. - EW

EW Key Data

Open

$80.80

 Day Range

79.53 - 80.80

52 Week Range

64.01 - 83.00

 Market Cap

$47.52B

Shares Outstanding

587.10M

 Public Float

575.06M

Beta

1.07

 Rev. Per Employee

N/A

P/E Ratio

55.26

 EPS

$1.47

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

3.69M

  

EW Performance

1 Week
 
 -0.49%
 
1 Month
 
 3.31%
 
3 Months
 
 4.41%
 
1 Year
 
 21.15%
 
5 Years
 
 -1.03%
 

EW Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 35
Full Ratings ➔

About edwards lifesciences corp. - EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

EW At a Glance

Edwards Lifesciences Corp.
1 Edwards Way
Irvine, California 92614
Phone 1-949-250-2500 Revenue 5.44B
Industry Medical Specialties Net Income 874.60M
Sector Health Technology Employees 15,800
Fiscal Year-end 12 / 2025
View SEC Filings

EW Valuation

P/E Current 55.257
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 50.726
Price to Sales Ratio 8.156
Price to Book Ratio 4.358
Price to Cash Flow Ratio 81.811
Enterprise Value to EBITDA 25.728
Enterprise Value to Sales 7.565
Total Debt to Enterprise Value 0.017

EW Efficiency

Revenue/Employee 344,272.152
Income Per Employee 55,354.43
Receivables Turnover 7.478
Total Asset Turnover 0.485

EW Liquidity

Current Ratio 4.176
Quick Ratio 3.454
Cash Ratio 2.644

EW Profitability

Gross Margin 78.798
Operating Margin 26.552
Pretax Margin 28.46
Net Margin 16.079
Return on Assets 12.498
Return on Equity 16.829
Return on Total Capital 13.094
Return on Invested Capital 15.57

EW Capital Structure

Total Debt to Total Equity 7.001
Total Debt to Total Capital 6.543
Total Debt to Total Assets 5.362
Long-Term Debt to Equity 6.767
Long-Term Debt to Total Capital 6.324
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Edwards Lifesciences Corp. - EW

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
5.23B 5.38B 6.00B 5.44B
Sales Growth
+19.29% +2.86% +11.56% -9.41%
Cost of Goods Sold (COGS) incl D&A
1.23B 1.17B 1.44B 1.15B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
163.30M 166.80M 145.00M 155.20M
Depreciation
155.60M 161.10M 138.90M 149.60M
Amortization of Intangibles
7.70M 5.70M 6.10M 5.60M
COGS Growth
+11.55% -4.79% +23.26% -19.84%
Gross Income
4.01B 4.22B 4.57B 4.29B
Gross Income Growth
+21.88% +5.21% +8.32% -6.13%
Gross Profit Margin
+76.57% +78.31% +76.04% +78.80%
2021 2022 2023 2024 5-year trend
SG&A Expense
2.40B 2.51B 2.90B 2.84B
Research & Development
903.10M 945.20M 1.07B 1.05B
Other SG&A
1.49B 1.57B 1.82B 1.79B
SGA Growth
+20.33% +4.87% +15.27% -1.87%
Other Operating Expense
- - - (300.00K)
-
Unusual Expense
(130.90M) (1.60M) 173.20M 41.60M
EBIT after Unusual Expense
1.74B 1.70B 1.50B 1.40B
Non Operating Income/Expense
(14.50M) 89.60M 126.10M 165.20M
Non-Operating Interest Income
17.40M 35.50M 67.20M 120.30M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
24.80M 26.20M 24.50M 19.80M
Interest Expense Growth
+11.71% +5.65% -6.49% -19.18%
Gross Interest Expense
24.80M 26.20M 24.50M 19.80M
Interest Capitalized
- - - -
-
Pretax Income
1.70B 1.77B 1.60B 1.55B
Pretax Income Growth
+85.67% +3.84% -9.58% -3.13%
Pretax Margin
+32.53% +32.84% +26.61% +28.46%
Income Tax
198.90M 245.50M 198.70M 152.10M
Income Tax - Current - Domestic
150.30M 429.70M 375.40M 289.10M
Income Tax - Current - Foreign
92.60M 66.70M 85.30M 25.80M
Income Tax - Deferred - Domestic
(34.80M) (246.60M) (241.70M) (148.80M)
Income Tax - Deferred - Foreign
(9.20M) (4.30M) (20.30M) (14.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.50B 1.52B 1.40B 1.40B
Minority Interest Expense
- - (3.00M) (4.90M)
-
Net Income
1.50B 1.52B 1.40B 1.40B
Net Income Growth
+82.55% +1.25% -7.85% -0.11%
Net Margin Growth
+28.73% +28.28% +23.35% +25.75%
Extraordinaries & Discontinued Operations
- - - (526.30M)
-
Discontinued Operations
- - - (526.30M)
-
Net Income After Extraordinaries
1.50B 1.52B 1.40B 874.60M
Preferred Dividends
- - - -
-
Net Income Available to Common
1.50B 1.52B 1.40B 874.60M
EPS (Basic)
2.4115 2.4586 2.3115 1.4633
EPS (Basic) Growth
+82.34% +1.95% -5.98% -36.69%
Basic Shares Outstanding
623.30M 619.00M 606.70M 597.70M
EPS (Diluted)
2.3813 2.4382 2.3013 1.4594
EPS (Diluted) Growth
+82.76% +2.39% -5.61% -36.58%
Diluted Shares Outstanding
631.20M 624.20M 609.40M 599.30M
EBITDA
1.77B 1.87B 1.81B 1.60B
EBITDA Growth
+23.91% +5.38% -2.92% -11.86%
EBITDA Margin
+33.90% +34.73% +30.22% +29.41%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 88.429
Number of Ratings 35 Current Quarters Estimate 0.591
FY Report Date 09 / 2025 Current Year's Estimate 2.503
Last Quarter’s Earnings 0.67 Median PE on CY Estimate N/A
Year Ago Earnings 2.43 Next Fiscal Year Estimate 2.792
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 27 27 31 31
Mean Estimate 0.59 0.61 2.50 2.79
High Estimates 0.64 0.70 2.55 2.93
Low Estimate 0.56 0.56 2.47 2.72
Coefficient of Variance 2.69 5.09 0.90 1.82

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 16 16 13
OVERWEIGHT 4 4 3
HOLD 14 14 14
UNDERWEIGHT 0 1 1
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Edwards Lifesciences Corp. - EW

Date Name Shares Transaction Value
Jul 29, 2025 Daniel J. Lippis CVP, JAPAC 22,002 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $79.46 per share 1,748,278.92
Apr 15, 2025 Donald E. Bobo CVP,Strategy/Corp Development N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 15, 2025 Donald E. Bobo CVP,Strategy/Corp Development 47,206 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.81 per share 3,295,450.86
Apr 15, 2025 Donald E. Bobo CVP,Strategy/Corp Development 56,706 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $45.28 per share 2,567,647.68
Apr 9, 2025 Daniel J. Lippis CVP, JAPAC 330 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 9, 2025 Daniel J. Lippis CVP, JAPAC 22,863 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.61 per share 1,614,356.43
Mar 11, 2025 Bernard J. Zovighian CEO; Director 66,546 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $45.28 per share 3,013,202.88
Mar 11, 2025 Bernard J. Zovighian CEO; Director 65,247 Bona fide gift 0.00
Mar 11, 2025 Bernard J. Zovighian CEO; Director 59,083 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.51 per share 4,106,859.33
Mar 11, 2025 Bernard J. Zovighian CEO; Director 10,436 Bona fide gift 0.00
Mar 11, 2025 Bernard J. Zovighian CEO; Director 7,462 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2025 Scott B. Ullem CVP, Chief Financial Officer 22,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2025 Scott B. Ullem CVP, Chief Financial Officer 30,387 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.52 per share 2,142,891.24
Mar 3, 2025 Scott B. Ullem CVP, Chief Financial Officer 38,147 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $71.38 per share 2,722,932.86
Mar 3, 2025 Scott B. Ullem CVP, Chief Financial Officer 41,637 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $45.28 per share 1,885,323.36
Feb 17, 2025 Steven R. Loranger Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 17, 2025 Steven R. Loranger Director 60,372 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $76.42 per share 4,613,628.24
Feb 17, 2025 Steven R. Loranger Director 66,111 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $45.32 per share 2,996,150.52

Edwards Lifesciences Corp. in the News